HXN6005
/ Helixon Biotechnology (Suzhou)
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 25, 2026
Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
(clinicaltrials.gov)
- P1/2 | N=67 | Not yet recruiting | Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd
New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 1
Of
1
Go to page
1